TABLE 3.
Outcomes of Cancer COVID‐19 Cohort, COVID‐19 Cohort, and Cancer Cohort
| Patients, no. (%) | |||||
|---|---|---|---|---|---|
| Cancer COVID‐19 cohort (n = 166) | COVID‐19 cohort (n = 498) | P value a | Cancer cohort (n = 498) | P value b | |
| COVID‐19 severity | |||||
| Non‐severe | 106 (64) | 399 (80) | <.001 | NA | NA |
| Severe | 60 (36) | 99 (20) | NA | NA | |
| Oxygenation and ventilation | |||||
| Not requiring supplement oxygen | 47 (29) | 170 (34) | <.001 | NA | NA |
| Requiring supplement oxygen | 93 (56) | 279 (56) | NA | NA | |
| HFNC | 2 (1) | 23 (5) | NA | NA | |
| NIV | 11 (7) | 8 (2) | NA | NA | |
| IMV or ECMO | 12 (7) | 18 (4) | NA | NA | |
| Length of hospital stay, median (IQR), d | 25 (15–33) | 21 (11–28) | .005 | NA | NA |
| Time from symptom onset to admission, median (IQR), d | 10 (7–16) | 10 (5–15) | .047 | NA | NA |
| Time from admission to follow‐up, median (IQR), m | 12.2 (12.1–12.6) | 12.2 (12.1–12.6) | .36 | 12.1 (11.7–12.4) | .063 |
| Time from discharge to follow‐up, median (IQR), m | 11.2 (10.8–11.6) | 11.4 (11.2–11.8) | .051 | 11.2 (10.7–11.7) | .82 |
| Mortality | |||||
| 1‐year all‐cause mortality | 49 (30) | 44 (9) | <.001 | 80 (16) | <.001 |
| 12‐month post‐discharge mortality | 15 (11) | 2 (0.4) | <.001 | 72 (15) | .084 |
| Hospital mortality | 34 (20) | 42 (8) | <.001 | 8 (2) c | <.001 |
| Consequences at 1‐year followed up | |||||
| Number of patients | 114 | 432 | NA | NA | |
| Any one of symptoms | 26 (23) | 130 (30) | 0.13 | NA | NA |
| Fatigue | 5 (4) | 53 (12) | 0.016 | NA | NA |
| Chest congestion | 3 (3) | 38 (9) | 0.027 | NA | NA |
| Cough | 10 (9) | 25 (6) | 0.24 | NA | NA |
| Expectoration | 4 (4) | 7 (2) | 0.20 | NA | NA |
| Dyspnea | 9 (8) | 27 (6) | 0.51 | NA | NA |
| Palpitations | 2 (2) | 9 (2) | 0.83 | NA | NA |
| Waist pain | 7 (6) | 20 (5) | 0.50 | NA | NA |
| Anxiety | 0 | 23 (5) | 0.021 | NA | NA |
| Sleep difficulties | 1 (1) | 5 (1) | 0.65 | NA | NA |
Abbreviations: ECMO, Extracorporeal membrane oxygenation; HFNC, high‐flow nasal canula for oxygen therapy; IMV, Invasive mechanical ventilation; NIV, Noninvasive mechanical ventilation.
a
Cancer COVID‐19 cohort vs COVID‐19 cohort.
b
Cancer COVID‐19 cohort vs cancer cohort.
c
As these patients were not necessarily hospitalized, their hospital mortality rate was calculated as when one deceased within the hospitalization time duration of their cancer COVID‐19 cohort match patient.